New Delhi, July 22 -- Small-cap stock Godavari Biorefineries' shares hit their upper circuit on Tuesday, 22 July 2025, after the company secured a patent for its "novel anti-cancer molecule" from China's patent and trademark office, according to an exchange filing.

"Godavari Biorefineries Ltd, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office, for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE," the company informed the BSE through the filing.

Godavari Biorefineries is a major producer of ethanol and ethanol-based chemicals in India. The company manufactures bio-based chemicals,...